Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type.

Trial Profile

Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2012

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Panitumumab (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms PaLiDo
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Oct 2011 Planned end date changed from 1 Dec 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 24 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top